Biocytogen Closes $65 Million Round for Animal Model CRO Services

Biocytogen of Beijing closed a $65 million series C funding to support its CRO operations. Founded in 2009, the company provides gene engineered animal models, preclinical animal studies and other services that include large-scale animal model supply. It also offers preclinical animal studies using gene humanized models, PDX models and reconstructed human immune system models. Biocytogen works with well-known academic institutions in the US and China , as well as biopharmas' R&D departments. More details.... Share this with colleagues: // //